GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025. The presentation will focus on the company's progress in developing vaccines for infectious diseases and therapies for cancer, including updates on the GEO-MVA, GEO-CM04S1, and Gedeptin® programs. This event is significant for investors and the medical community as it provides insights into potential advancements in vaccine technology and cancer treatment.
The GEO-MVA program, aimed at combating Mpox and smallpox, has recently received favorable feedback from the European Medicines Agency, marking a critical step towards global vaccine preparedness. Meanwhile, the GEO-CM04S1 COVID-19 vaccine is undergoing Phase 2 clinical trials, targeting immunocompromised individuals and healthy adults, offering hope for more effective protection against the virus. Additionally, the Gedeptin® program is preparing for a Phase 2 trial in head and neck cancer, showcasing GeoVax's commitment to addressing unmet needs in oncology.
GeoVax's participation in the conference underscores the importance of its MVA platform and U.S.-based manufacturing capabilities in enhancing vaccine supply diversification and pandemic readiness. The presentation by Chairman and CEO David Dodd will not only highlight these achievements but also engage the investment community in a real-time Q&A session, fostering transparency and collaboration.
For those interested in attending the conference or accessing the replay, registration and details are available at https://goto.webcasts.com/starthere.jsp?ei=1717085&tp_key=408af67859&sti=govx. This event represents a pivotal moment for GeoVax and the broader biotech industry, as it showcases innovative solutions to some of today's most pressing health challenges.
